Abandoned AstraZeneca Compounds “Given” To U.K. R&D Academics
This article was originally published in The Pink Sheet Daily
AstraZeneca is giving 15 shelved compounds to U.K.-based academics in a collaboration funded by public money that may produce scientific breakthroughs along with thorny IP issues.
You may also be interested in...
Britain moves ahead with a drug-repurposing research program that brings together big pharma and academic researchers in novel collaborations.
Seeing Is Believing: GSK Pledges To Upgrade Key Antibiotics Plant As Witty Hosts Q3 Call From Singapore
During a celebration to mark GSK’s 40th year in Singapore, CEO Andrew Witty announces new investments in work-horse manufacturing plants and reaffirms openness to share patient data from clinical studies.
With collaborative research agreement templates that include many of the details for a licensing agreement, royalties will be the major issue to be resolved if researchers develop new IP for one of the firm’s abandoned compounds.